Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 3/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.31 |
| ▸ | AQP1 | P29972 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10098116 | 0.87 | NFE2L2 (0.32) | NFE2L2 | |
| SCHEMBL10098119 | 0.87 | NFE2L2 (0.32) | NFE2L2 | |
| SCHEMBL10097118 | 0.86 | NFE2L2 (0.39) | NFE2L2PTGS1PTGS2ALOX5CA1 | |
| SCHEMBL10098266 | 0.84 | NFE2L2 (0.35) | NFE2L2PTGS1PTGS2ALOX5CA1 | |
| SCHEMBL10098341 | 0.80 | — | — | |
| SCHEMBL10097999 | 0.77 | — | — | |
| SCHEMBL10097051 | 0.74 | NFE2L2 (0.33) | NFE2L2 | |
| SCHEMBL10097972 | 0.70 | HPGD (0.31) | — | |
| SCHEMBL10096906 | 0.70 | NFE2L2 (0.37) | NFE2L2PTGS1PTGS2ALOX5 | |
| SCHEMBL10097092 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124196-B2 | Fluorobicyclo[2.2.2]octane compound, method of producing the same, and applications thereof | FUJIFILM CORPORATION (JP) | 2012-02-28 | — | — | US | disclosed |
| US-20100231844-A1 | FLUOROBICYCLO[2.2.2]OCTANE COMPOUND, METHOD OF PRODUCING THE SAME, AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100231844-A1 | FLUOROBICYCLO[2.2.2]OCTANE COMPOUND, METHOD OF PRODUCING THE SAME, AND APPLICATIONS THEREOF | AFF2, FPR2, SLCO1A2 | NFE2L2 636/4885PTGS1 4475/4885PTGS2 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.